EVO (Evotec SE) Beta: 2.4128 (As of Jun. 26, 2026)


EVO Evotec SE EVO
64 GF Score
Price $2.74
GF Value $4.27
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Evotec SE Beta?

Evotec SE EVO +1.11% 64 Beta is 2.4128 as of Jun. 26, 2026. GuruFocus rates EVO with a GF Score™ of 64/100 and a GF Value™ of $4.27 (Possible Value Trap). The stock has 5 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-26), Evotec SE's Beta is 2.4128.


Evotec SE  (NAS:EVO) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Evotec SE Beta Related Terms


Evotec SE Beta Historical Data

* Premium members only.

The historical data trend for Evotec SE's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evotec SE Beta Chart

Evotec SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.90 1.18 1.81 1.92 2.35

Evotec SE Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.88 1.85 1.97 2.35 2.24

EVO vs ZTS, UTHR, VTRS: Beta Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Evotec SE's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evotec SE Beta vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Evotec SE's Beta distribution charts can be found below:

* The bar in red indicates where Evotec SE's Beta falls into.


EVO
64GF Score
Evotec SE EVO
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Evotec SE Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 2.4128 mean?
Evotec SE (EVO) has a Beta of 2.4128 as of Jun. 26, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Evotec SE and its competitors.
Is Evotec SE's Beta too high?
Evotec SE's current Beta is 2.4128. Overall, Evotec SE has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evotec SE's Beta compare to ZTS and UTHR?
Evotec SE's Beta of 2.4128 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Drug Manufacturers company?
A good Beta depends on the Drug Manufacturers industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Evotec SE and its competitors. Evotec SE's current Beta is 2.4128. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evotec SE stock overvalued right now?
Based on GuruFocus' analysis, Evotec SE (EVO) is currently considered Possible Value Trap. The stock's GF Value™ is $4.27, compared to a current price of $2.74 — trading 35.8% below its estimated fair value. The current Beta is 2.4128. Evotec SE's overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Evotec SE (EVO), the current Beta is 2.4128 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Evotec SE (EVO) Overvalued in 2026?

Based on GuruFocus' analysis, Evotec SE stock appears to be undervalued. The current stock price of $2.74 is trading 35.8% below its estimated GF Value™ of $4.27. GuruFocus considers Evotec SE to be Possible Value Trap.

Key valuation signals for EVO:

  • Beta: 2.4128
  • GF Value™: $4.27 vs. price of $2.74 (35.8% below fair value)
  • GF Score™: 64/100 with 5 warning signs

No single metric tells the full story. See the EVO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Evotec SE Business Description

Address Essener Bogen 7, 22419 Hamburg, Hamburg, DEU, 22419
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
64GF Score

Get the complete analysis for EVO

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.74
Price
$4.27
GF Value